RT Journal Article
T1 Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post‐transplantation cyclophosphamide
A1 Huntley, Dixie
A1 Giménez, Estela
A1 Pascual, María Jesús
A1 Hernández Boluda, Juan Carlos
A1 Gago, Beatriz
A1 Vázquez, Lourdes
A1 Piñana, José Luis
A1 García, Magdalena
A1 Pérez, Ariadna
A1 Serrano, David
A1 Hernández Martín, Marta María
A1 Albert, Eliseo
A1 Solano, Carlos
A1 Navarro, David
AB Background: Conflicting data have been published as to the risk of cytomegalovirus (CMV) DNAemia and CMV disease in patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantationcyclophosphamide.Methods: We conducted a multicenter retrospective study including 118 patients subjected to unmanipulated haplo-HSCT to further clarify this issue. An historic cohort comprising 165 patients undergoing other transplant modalities (HLA-matched related, matched unrelated or mismatched) was built for comparison purposes. Plasma CMV DNA monitoring was performed using two highly sensitive real-time PCR assays.Results: Overall, the cumulative incidence of CMV DNAemia, recurrent CMV DNAemia, and CMV DNAemia requiring preemptive antiviral therapy in patients undergoinghaplo-HSCT was 63.9%, 34.9%, and 50.1%, respectively. These figures were rathercomparable for other transplant modalities (P = .22, P = .13 and P = .72, respectively).A trend toward longer duration of episodes and shorter CMV DNA doubling timeswas observed in haplo-HSCT patients in comparison with other transplant modalities.Furthermore, median CMV DNA peak load was significantly higher in haplo-HSCTs(P = .008), yet overall mortality by day 180 and 365 was the same across comparisongroups. There were five cases of CMV disease, and all occurred in haplo-HSCT patients.This latter observation is worrying and merits further investigation.Conclusions: The incidence of initial and recurrent episodes of CMV DNAemia eitherrequiring or not antiviral therapy in unmanipulated haplo-HSCT was comparable toother transplant modalities in our cohort.
PB Wiley
SN 1398-2273
SN 1399-3062
YR 2019
FD 2019-11-15
LK https://hdl.handle.net/20.500.14352/108183
UL https://hdl.handle.net/20.500.14352/108183
LA eng
NO Huntley D, Giménez E, Pascual MJ, et al. Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplantation cyclophosphamide. Transpl Infect Dis. 2020;22:e13206. https ://doi.org/10.1111/tid.13206
DS Docta Complutense
RD 21 abr 2025